Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, by Drug Type (Oral & Parenteral Antibiotics {Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others)}, and Topical Antibiotics {Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine}), by Infection Type (Hospital Acquired ABSSSI, and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 10,263.5 million in 2022 and is expected to exhibit a CAGR of 9.0% over the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

Key players operating in market are focusing on receiving drug approvals from regulatory authorities and this is expected to drive the global acute bacterial skin and skin structure infections (ABSSSI) market growth over the forecast period.

For instance, in October 2018, Paratek Pharmaceuticals, Inc., a U.S. biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has approved Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute skin and skin structure infections (ABSSSI). Nuzyra, a modernized tetracycline, is a once-daily intravenous (IV) and oral antibiotic that exhibits activity across a spectrum of bacteria, including Gram-positive, Gram-negative, and drug resistant strains.

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – Impact of Coronavirus (Covid-19) Pandemic

COVID-19 outbreak was first reported on December 31, 2019, in Wuhan, China. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 519 million cases and 6.3 million deaths due to Coronavirus (COVID-19) were reported up till May 15, 2022, across the globe.

The COVID-19 pandemic has adversely affected several markets across the globe and it is expected to have a similar impact on the global acute bacterial skin and skin structure infections (ABSSSI) market, owing to disruptions in supply of raw materials required for drug production and lockdowns in several countries across the world. Lockdowns in various countries have placed an economic burden on the private healthcare sector. Healthcare providers are facing challenges in terms of availability of manpower, equipment, consumables, and other resources to ensure safe treatment of patients with other diseases, and declining outpatient’s visits among others.

Moreover, the coronavirus pandemic has negatively impacted development, production, and supply of drugs and affected growth of the healthcare businesses of various companies across the globe, which has led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of products.

Browse 49 Market Data Tables and 35 Figures spread through 180 Pages and in-depth TOC on “Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market”- Global Forecast to 2030, by Drug Type (Oral & Parenteral Antibiotics {Vancomycin, Linezolid, Clindamycin, Ceftaroline, Daptomycin, Dalbavancin, Tedizolid, and Others (Rifampin, Doxycycline, Minocycline, and Trimethoprim-Sulfa Methoxazol, among others)}, and Topical Antibiotics {Hydrogen Peroxide, Fusidic Acid, Mupirocin, Retapamulin, and Povidone-Iodine}), by Infection Type (Hospital Acquired ABSSSI, and Community Acquired ABSSSI), by Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa),

To know the latest trends and insights prevalent in the global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market, click the link below:

https://www.coherentmarketinsights.com/market-insight/acute-bacterial-skin-and-skin-structure-infections-absssi-market-1531

Key players operating in market are focusing on adoption of inorganic growth strategies such as partnerships, and others in order to strengthen their position in the market. In July, Nabriva Therapeutics plc, an Ireland-based biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, entered an exclusive agreement with subsidiaries of Merck & Co. Inc., U.S. to market, sell and distribute Sivextro in the U.S. for treatment of acute bacterial skin and skin structure infections (ABSSSI).

Key Takeaways of the Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market:

  • Global acute bacterial skin and skin structure infections (ABSSSI) market is expected to exhibit a CAGR of 9.0% over the forecast period, owing to rising research and development activities by market players for development of acute bacterial skin and skin structure infections (ABSSSI) therapeutics. For instance, in June 2019, Motif Bio Plc, a UK based clinical-stage biopharmaceutical company specializing in developing novel antibiotics, reported that new and promising Iclaprim data were presented at the American Society For Microbiology (ASM) Microbe 2019 meeting held in San Francisco, California, U.S. Iclaprim demonstrated potent activity against various Gram-positive multi-drug resistant streptococci that were collected from patients with ABSSSI between 2013 and 2017 in locations around the world.
  • Among distribution channel, hospital pharmacies segment is expected to account for the largest market share in 2022 as hospitals are the primary distribution channel for both generic and branded antibiotics for different types of ABSSSI. Moreover, increasing hospital expenditure across the globe expected to provide strong growth prospects over the forecast period. For instance, according to The Centers for Medicare and Medicaid Services’ 2020 findings on the National Health Expenditure (NHE) updated in December 2021, hospital expenditure in U.S. grew by 6.4% to US$ 1,270.1 billion in 2020 compared to 2019. Moreover, prescription drug spending increased by 3.0% to US$ 348.4 billion in the U.S. in 2020, as compared to 2019.
  • Key players operating in the global acute bacterial skin and skin structure infections (ABSSSI) market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie, Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sandoz Inc., Glenmark Pharmaceuticals Ltd, and Cadila Healthcare Ltd.

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo